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Abstract
Background:  CD5 is a pan-T cell surface marker that is also present on a subset of B cells, B-1a
cells.Functional and developmental subsets of T cells express characteristic CD5 levels that vary
over roughly a 30-fold range. Previous investigators have cloned a 1.7 Kb fragment containing the
CD5 promoter and showed that it can confer similar lymphocyte-specific expression pattern as
observed for endogenous CD5 expression.
Results:  We further characterize the CD5 promoter and identify minimal and regulatory regions
on the CD5 promoter. Using a luciferase reporter system, we show that a 43 bp region on the
CD5 promoter regulates CD5 expression in resting mouse thymoma EL4 T cells and that an Ets
binding site within the 43 bp region mediates the CD5 expression. In addition, we show that Ets-
1, a member of the Ets family of transcription factors, recognizes the Ets binding site in the
electrophoretic mobility shift assay (EMSA). This Ets binding site is directly responsible for the
increase in reporter activity when co-transfected with increasing amounts of Ets-1 expression
plasmid.
We also identify two additional evolutionarily-conserved regions in the CD5 promoter (CD5X and
CD5Y)  and  demonstrate  the  respective  roles  of  the  each  region  in  the  regulation  of  CD5
transcription.
Conclusion:  Our studies define a minimal and regulatory promoter for CD5 and show that the
CD5 expression level in T cells is at least partially dependent on the level of Ets-1 protein. Based
on the findings in this report, we propose a model of CD5 transcriptional regulation in T cells.
Introduction
The murine CD5 protein (Ly-1), a 67 kD membrane-asso-
ciated glycoprotein found on all T cells and at low levels
on B-1a cells, a CD5-expressing subset of B lymphocytes
[1,2,3,4]. CD5 levels on the developmental and function-
al subsets range are ordered in a characteristic fashion:
Thymic CD4+ T > Splenic CD4+ T > Thymic CD8+ T >
Splenic CD8+ T > Thymic CD4+CD8+ T >> B-1a cells [5,
6]. The CD5 surface and mRNA expression levels in these
subsets are highly correlated, suggesting that CD5 ex-
pression is primarily regulated at the transcriptional lev-
el.
Structurally, CD5 belongs to the scavenger receptor fam-
ily of proteins based on the homology of its three extra-
cellular scavenger receptor cysteine-rich (SRCR)
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domains to other family members [7]. Several potential
CD5 ligands have been reported so far: the pan-B cell
marker, CD72 [8]; an as yet unidentified lymphocyte
specific inducible glycoprotein [9]; and, VH framework
determinants on immunoglobulins [10]. While none of
these potential ligands have been unequivocally shown
to physiologically interact with CD5, these potential CD5
receptor/ligand pairs suggest that CD5 may play a role in
T-B or B-1a-B cell-cell communication.
CD5 has been shown to be physically associated with the
T cell receptor (TCR)/CD3 complex in T cells and with B
cell receptor (BCR) in B-1a cells [11,12,13]. Although sev-
eral laboratories reported that crosslinking CD5 on the
surface augments T cells signaling by inducing calcium
flux and enhancing mitogenic response [14,15,16], recent
studies using CD5-deficient mice indicate that CD5 may
be more important as a negative modulator of TCR and
BCR signal transduction [17, 18]. Consistent with this
idea, the positive and negative selection in the thymus of
CD5-deficient mice is altered in that their thymocytes are
hyperresponsive and hyperproliferative to activation in-
duced by anti-CD3 antibodies [17]. Similarly, CD5-defi-
cient B-1a cells show higher proliferative responses to
surface IgM ligation than heterozygote littermates [18].
CD5 most likely exerts its negative modulation of recep-
tor signal transduction by associating with SH-2-con-
taining signaling molecules. This association could be
directed by an imperfect immunoreceptor tyrosine-
based activating motif (ITAM) [19] or by a motif similar
to immunoreceptor tyrosine-based inhibitory motif (IT-
IM) located in the CD5 cytoplasmic domain [20]. Con-
sistent with SH-2 interaction, CD5 cytoplasmic tyrosine
residues are phosphorylated by p56lck kinases upon
TCR/CD3 ligation and serve as targets for association
with proteins containing SH2 domains in both T and B-
1a cells [12, 21, 22].
In human Jurkat cells and phytohemagglutinin-expand-
ed T lymphoblasts, the CD5 ITIM-like motif is crucial for
association with SHP-1, a cytosolic tyrosine phosphotase
implicated in the negative regulation of antigen receptor-
mediated signaling [23]. However, in murine B lympho-
ma cells, the CD5 pseudo-ITAM motif mediates its inhib-
itory action via a SHP-1 independent mechanism [24].
Several studies have examined the CD5 promoter. Com-
parison of the sequences of the CD5 promoters cloned
from man and mouse [25, 26] revealed conserved tran-
scription factor binding sites. In addition, deletion anal-
ysis of the murine CD5 promoter indicated the presence
of lymphoid-specific regulatory elements [25].
Here, we present a detailed analysis of the CD5 promot-
er. Using unstimulated EL4 thymoma cells as a model
system, we demonstrate that a CD5 expression is regulat-
ed by a 43 bp region (-172 to -215 bp) upstream of the
methionine start codon for CD5. The presence of the Ets
binding site in this regulatory region is particularly inter-
esting because levels of Ets-1, a lymphoid-specific mem-
ber of the Ets family [27, 28], have been shown to closely
resemble the mRNA and protein levels observed for CD5
in different T cell subsets [29] [5,6]. In addition, CD5
surface protein expression is greatly reduced in ets-1-/- T
cells [30, 31].
We show here that Ets-1 protein recognizes and binds the
Ets site in the 43 bp regulatory region and that CD5 ex-
pression is positively correlated with Ets-1 levels in co-
transfection studies. Thus, we closely link Ets-1 to CD5
regulation. In addition, we show that two other evolu-
tionarily conserved regions located close to the Ets site
(provisionally named CD5X and CD5Y) play a role in
CD5 expression. Based on these data, we propose a mod-
el for CD5 transcriptional control in resting T cells that
includes interaction between CD5X, CD5Y and Ets-1.
Results
Characterization of regions on the CD5 promoter neces-
sary for CD5 transcription
We constructed luciferase reporter constructs containing
progressively deleted fragments of a 3 kb genomic DNA
clone which contains the CD5 promoter [1, 32] (Figure
1a). Each deletion (luciferase) construct and a control
LacZ reporter construct (pON405) were co-transfected
into the EL4 T cell line and lysates prepared after cells
were grown for 36-48 hours were assayed for luciferase
activity.
Results show that the 3 kb fragment induces a large in-
crease in luciferase activity, which we define as the full
level of CD5 expression in resting T cells (Figure 1b).
Transfections with constructs containing successive de-
letions of the 3 kb fragment show that removal of DNA
regions upstream of a StuI site (at -215, relative to the
CD5 protein initiation methionine codon) does not sig-
nificantly decrease luciferase expression from the level
obtained with the full length fragment. However, the de-
letion of an additional 43 bp (from StuI to HincII site at
-172) reduces the reporter activity by more than five-fold
to basal level, which is somewhat higher than the back-
ground level obtained with a promoterless luciferase
construct (GLB = pGLBasic). Additional deletion from
the HincII to the HinfI site at -67 further reduced the ba-
sal reporter activity down to the background level. These
deletion constructs define two regions as important for
CD5 expression: a minimal/core promoter region (Hin-
cII to HinfI site) that is required for basal activity and aBMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
regulatory region necessary for the full CD5 expression
(StuI to HincII) site in resting T cells.
The Ets binding site is important for full CD5 expression
Three potential transcription factor binding sites -
CCAAT, κ E2, and Ets - were previously identified by da-
tabase sequence comparison in the 43 bp region de-
scribed above (StuI to HincII) [25]. However, only the
κ E2 and Ets site are conserved between mouse and hu-
man [26]. To determine which of these potential tran-
scription factor binding sites is responsible for
regulating normal CD5 expression, we performed site-
directed mutagenesis on the CCAAT (mutC), κ E2 (mutK)
and Ets (mutE) sites from the StuI B reporter construct.
Wild-type control and the mutant constructs were tested
for their promoter activity in EL4 cells. As figure 2
shows, mutations in the CCAAT or κ E2 binding site re-
sulted in minor reductions in reporter activity. In con-
trast, the mutation in the Ets binding site completely
abolished the full induction of transcription and reduced
the luciferase activity to the basal level.
Figure 1
a. CD5 promoter deletion constructs. The 3 kb CD5 5-
flanking region fragment was excised from p12-1 and subject
to 5' to 3' deletion with SspI (-785), RsaI (-530), AciI (-257),
StuI (-215), HincII (-172), HinfI (-67). The deleted CD5 5'-
flanking regions were cloned into a promoterless luciferase
construct, pGLB (Promega). The DNA base pair on the CD5
promoter, before the translation start, is labeled as -1.
 b. A 43 bp region in the CD5 promoter is responsible
for normal expression in EL4 (T) cells. EL4 cells were
transiently co-transfected with each deletion construct and
pON405, a LacZ reporter construct, as described in Materi-
als and Methods. Luciferase activity in cell extracts was meas-
u r e d  b e t w e e n  3 6  a n d  4 8  h o u r s  a f t e r  t r a n s f e c t i o n .  T h e
measurement for luciferase activity was normalized based on
the  β -galactosidase  activity  in  each  cell  extract.  Each  bar
value represents the average of three independent transfec-
tions in one experiment, with standard deviation as error
bars. Each experiment was repeated several times.
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Figure 2
Site-directed mutagenesis of the 43 region (StuI to
HincII) identified an Ets binding site on the CD5 pro-
moter as necessary for maximal CD5 promoter. Each
o f  t h e  t h r e e  p o t e n t i a l  t r a n s c r i p t i o n  f a c t o r  b i n d i n g  s i t e s -
CCAAT, κ E2, and Ets, was mutated on the StuI B reporter
construct as described in Materials and Methods. EL4 cells
were transiently transfected with StuI B, mutC StuI B, mutK
StuI B, mutE StuI B, or HincII B constructs, and with pON405
LacZ re port er plas mid  as inte rnal cont rol. Eac h bar value
represents the average of three independent transfections in
one experiment, with standard deviation as error bars.BMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
The Ets binding site is recognized by Ets-1 protein
The above experiments demonstrate that a potential Ets
binding site on the CD5 promoter is necessary for the full
induction of transcription. Since Ets-1 is lymphoid-spe-
cific, and its expression levels in T cell subsets correlate
with the CD5 expression levels, we focused our study on
Ets-1 interaction with this Ets binding site.
For the following experiments we used an Ets-1 expres-
sion plasmid (pEVRF-ets-1) which encodes Ets-1 protein
[33, 34]. We then performed electrophoretic mobility
shift assays (EMSA) using radiolabelled Ets oligonucle-
otide with nuclear extracts prepared from pEVRF-ets-1
transfected M12 cells (figure 3a, lane 3-9). This olignu-
cleotide corresponds to the Ets binding site in the 43 bp
regulatory region of the CD5 promoter. It has the core
Ets binding concensus with and additional 6 bases on
each side.
The pEVRF-ets-1 transfected M12 nuclear extracts form
an additional protein:DNA complex (complex 1, figure 3,
lane 3) compared with the nuclear extracts from M12
cells transfected with the control plasmid, pEVRF0 (fig-
ure 3, lane 2). This complex is easily competed away by
increasing amount of unlabeled Ets oligos (figure 3,
lanes 4 and 5) but not by increasing amounts of irrele-
vant κ E2 oligos (figure 3, lanes 6 and 7). Furthermore, its
formation is prevented by pre-incubating the nuclear ex-
tract with anti-Ets-1 polyclonal antibodies, which recog-
nize the Ets-1 DNA binding domain (figure 3, lane 8), but
not by pre-incubation with pre-immune polyclonal anti-
bodies (figure 3, lane 9). Thus, this complex represents
true Ets-1 binding.
We observed two additional endogenous complexes
(complex 2 and 3) that were competed away with in-
creasing amount of unlabeled Ets oligos. However, these
two complexes were also competed away with increasing
amounts of irrelevant κ E2 oligos. Furthermore, complex
1 and 2 are not inhibited by pre-incubation with anti-Ets-
1 antibodies. Therefore, we conclude that complex 1 and
2 are not Ets-1 specific.
These competition and inhibition experiments demon-
strate that Ets-1 specifically binds to the oligonucleotide
used for these studies. As indicated above, this olignucle-
otide corresponds precisely to the Ets binding site in the
43 bp regulatory region of the CD5 promoter with the
core Ets binding concensus and only an additional 6 bas-
es on each side. Therefore, we conclude that Ets-1 binds
to the Ets site in the 43 bp regulatory region of the CD5
promoter or very closely to that site.
Ets-1 affects CD5 expression in T cells
To understand the effect of Ets-1 on CD5 expression, we
co-transfected EL4 cells with increasing amounts of Ets-
1 expression plasmid (pEVRF-ets-1) along with a StuI B
reporter construct containing either the wild type (S) or
mutated Ets binding site (E). As figure 4 shows, the luci-
ferase reporter activity from the wild type StuI B reporter
construct increased in a dose-dependent fashion with in-
creasing amounts of Ets-1 expression plasmid (lanes 1-
4). Importantly, the increase in reporter activity from
Ets-1 expression was mediated by the Ets binding site on
the CD5 promoter, as the increase in reporter expression
did not occur when the Ets binding site on the CD5 pro-
moter was mutated (lane 4 and 5).
Based on these transfections results and the EMSA ob-
servations described above, we conclude that Ets-1 regu-
lates CD5 expression by binding to the Ets site located
with in the 43 bp regulatory region.
The CD5Y region is essential for basal transcription in T 
cells
Using the Intelligenetics sequence analysis program to
compare the human and murine CD5 minimal promoter
regions, we found two conserved regions, provisionally
designated CD5X (-172 to -154) and CD5Y (-133 to -119)
(figure 5a), that abut the Ets binding site. These sequenc-
es did not show any homology to known transcription
factor binding sites. Transfection studies show that dele-
tion upstream of CD5X abolishes the regulatory promot-
er activity but does not hamper the basal promoter
activity. In contrast, deletion of the region containing
CD5X and CD5Y eliminates both the regulatory and ba-
sal promoter activity (figure 1b).
To determine whether the CD5X or CD5Y site is respon-
sible for basal level expression, we generated three muta-
tions encompassing the CD5X region (Xmut1, Xmut2,
and Xmut3) and two mutations on the CD5Y region of
the HincII B reporter plasmid (Ymut1 and Ymut2). These
mutant reporter constructs were transiently transfected
into EL4 cells and subsequently analyzed for luciferase
reporter activity.
None of the three mutated sites on the CD5X region had
any effect on the basal level of transcription (figure 5b).
In contrast, both mutations in the CD5Y region resulted
in reduction of the reporter activity. In fact, the luciferase
activity was reduced almost to background levels with
the Ymut1 mutation. Thus, we conclude that the CD5Y,
particularly the Ymut1 site, is important for basal tran-
scription.BMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
Figure 3
EMSA analysis of the ets binding site on the CD5 promoter. The 32P-labeled oligonucleotide probe containing the Ets
binding site (5' CGC GTA CAG GGA GGA AGT TGA CCT CGA 3') on the CD5 promoter was incubated with nuclear
extracts prepared from M12 cells. The Ets-1 protein:DNA complex is indicated as complex 1. Lane 1 is the probe alone; lane 2,
probe plus M12 nuclear extract from transfection with pEVRF0; and lane 3-9: probe plus M12 nuclear extract from transfection
pEVRF-ets-1. Competitive EMSA was performed using molar excess unlabeled olionucleotides as indicated: in lane 4, ten-fold
molar excess of unlabeled homologous Ets oligonucleotides; Lane 5, 100-fold molar excess of unlabeled Ets oligonucleotides;
Lane 6, ten-fold molar excess of unlabeled κ E2; and lane7, 100-fold molar excess of unlabeled κ E2 oligo. Inhibition EMSA was
also performed using antibodies as indicated: lane 8, anti-Ets-1 antibody; and lane 9, pre-immune antibody. F indicates the
migration of the free probe.BMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
Both CD5X and CD5Y regions affect full CD5 expression
To determine whether either the CD5X or the CD5Y re-
gion can affect the full level of transcription controlled by
the 43 bp CD5 regulatory promoter, we generated the
mutations described above in the CD5X and CD5Y re-
gions in the StuI B reporter construct. The Xmut2 muta-
tion had a measurable effect (2-fold decrease) on the full
level of transcription and the Ymut2 mutation reduced
the reporter activity by more than three-fold (figure 5c).
However, the Ymut1 mutation decreased the luciferase
activity more than five fold, and brought the transcrip-
tion activity to slightly below basal levels of CD5 tran-
scription (figure 5c). These results demonstrate that both
CD5X and CD5Y regions contribute to overall CD5 tran-
scription by modifying the transcriptional activation
from the 43 bp regulatory region and that the most im-
portant regulation comes from the CD5Y region.
EMSA analysis revealed specific proteins binding to the 
CD5X and CD5Y regions
We performed EMSA using oligonucleotide probes con-
taining either the CD5X or the CD5Y region to character-
ize protein binding to the respective regions. As figure 6a
shows, several protein complexes can be seen binding to
the 32P-labeled CD5X oligo (lane 2). Competition with
100-fold excess unlabeled CD5X oligo eliminated com-
plexes 1-3 (figure 6a, lane 3). These complexes are specif-
ic to the CD5X probes, as they can not be competed away
with the addition of excess irrelevant oligos, CD5Y, CK,
and KE (figure 6a, lanes 4-6).
Similarly, several protein:DNA complexes can be seen in
EMSA with 32P-labeled CD5Y oligo (figure 6b, lane 2).
Competition analysis demonstrated that complex 1 can
specifically be competed away by excess unlabeled CD5Y
oligo (figure 6b, lane 3) but not by excess, irrelevant
CD5X, CK, and KE oligos (figure 6b, lanes 4-6).
Thus we conclude that there are distinct intracellular
proteins that specifically bind to CD5X and CD5Y and
likely mediate the transcriptional activity of these newly
recognized sites.
Discussion
Studies here define the regions within the CD5 promoter
that control transcriptional regulation in resting (un-
stimulated) T cells growing in culture. By constructing a
deletion series of CD5 promoter constructs using luci-
ferase as the reporter gene, we demonstrate that a 43 bp
region between the StuI and HincII sites at -215 to -172
is necessary for normal, resting CD5 expression level in
T cells. Further, we show that this region contains an Ets
binding site that regulates CD5 transcription, two previ-
ously unrecognized regions that also control CD5 expres-
sion, one of which is responsible for controlling basal
expression of the promoter.
Weichert and Schwartz [25] have also reported a dele-
tion analysis of the CD5 promoter. Several of their dele-
tions overlap the deletions we report. For those
constructs which were similar in both studies, our results
agree. However, these workers observed negative regula-
tion with a construct that that we did not have. None of
our constructs showed negative regulation. We investi-
gated three potential transcription factor binding sites
(CCAAT, κ E2, and Ets) within the 43 bp regulatory pro-
moter region and showed that only the Ets binding site
influences CD5 expression in EL4 T cells. Further, we
showed that the Ets-1 protein binds to the Ets site and
that overexpression of Ets-1 leads to increased promoter
activity. Thus we conclude that Ets-1 positively regulates
CD5 expression levels in T cells.
Figure 4
Ets-1 affects CD5 expression levels. EL4 cells were tran-
siently transfected with StuI B reporter construct (S) plus dif-
ferent amounts of Ets-1 expression plasmid (pEVRF-ets-1): 5
µ g (lane 2), 10 µ g (lane 3), or 15 µ g (lane 4); or with StuI B
construct and 15 µ g control plasmid pEVRF0 (lane 1). EL4
cells  were  also  co-transfected  with  mutE  StuI  B  reporter
construct (E) and 15 µ g of pEVRF-ets-1 or pEVRF0 (lanes 5
and 6). Each bar value represents the average of three inde-
pendent transfections in one experiment, with standard devi-
ation as error bars.BMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
Figure 5
a: Sequence comparison of the Ets site, the CD5X region, and the CD5Y region between human and mouse.
Partial sequence alignment of the homologous regions on the mouse and human CD5 promoter, as determined by sequence
analysis program from Intelligenetics Corporation. The consensus sequences for the Ets, CD5X, and CD5Y regions are shown
in boxes.
b: Site-directed mutagenesis analysis showed that CD5Y region is important for basal CD5 transcription. Three
areas in CD5X region (Xmut1, Xmut2, and Xmut3) and two in CD5Y region (Ymut1 and Ymut2) were mutated by site-
directed mutagenesis on HincII B construct as described in Materials and Methods. Each mutant construct was cotransfected
with pON405 LacZ construct in EL4 cells. Wild-type HincII B and HinfI B constructs were also transfected as controls. Each
bar value represents the average of three independent transfections in one experiment, with standard deviation as error bars.
c: S ite- direct ed  mu ta gen esis ana lysis revealed th at  both  the CD5X and  CD5Y  regions affect overall CD5
expression. Three sites in the CD5X region (Xmut1, Xmut2, and Xmut3) and two in the CD5Y region (Xmut1 and Xmut2)
on the StuI B construct were mutated. Each X and Y mutant StuI B construct was co-transfected into EL4 cells along with
pON405 LacZ construct. Wild-type StuI B and HincII constructs were also transfected as controls.BMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
Theses findings are consistent with previous evidence
showing that Ets-1 levels in T cell subsets correlate with
the expression of CD5 on these subsets (see Introduction
to this paper). In addition, they are consistent with evi-
dence demonstrating that CD5 expression is drastically
reduced in gene targeted mice in which the Ets-1 locus is
disrupted. While the possibility that the decreased CD5
surface expression that was demonstrated in the gene
targeted mice is due to post-translational rather than
transcriptional effects, our co-transfection studies with
the Ets-1 expression plasmid and the CD5 promoter con-
structs demonstrate argue that Ets-1 is regulating tran-
scription in all cases. Thus, the weight of our findings, in
combination with findings with presented by others,
leads us to conclude that the distinctive CD5 expression
levels observed in T cell subsets is due to the different
amounts of Ets-1 protein in the cells in these subsets.
This conclusion does not eliminate the possibility that
Ets family members other than Ets-1 also participate in
the regulation of CD5 expression. PU.1, for example,
could be important in the regulation of CD5 expression
on B-1 cells, since it is predominantly expressed in B cells
and macrophages [35, 36]. In fact, preliminary evidence
from our laboratory suggests that this may indeed be the
case. Ets-2, which is ubiquitously expressed, could also
contribute to CD5 regulation [29, 37, 38]. However, the
data from Ets-1 gene targeted mice argues against this
possibility since disruption of the Ets-1 gene is sufficient
to prevent CD5 expression on T cells. Therefore, Ets-1 is
the likely regulatory molecule in T cells.
We also characterized two regions (CD5X and CD5Y)
that contribute to CD5 expression. These two regions,
which contain previously unrecognized transcription
binding factor sequence, are conserved between mouse
and human. Our results showed that the CD5Y region is
necessary for basal level of CD5 transcription. Computer
analysis of the CD5Y region did not reveal any potential
transcription factor binding site or a canonical TATA box
for establishing the typical RNA polymerase II transcrip-
tion complex. However, the Ymut1 site contains a very
weak homology to the TdT/ML intiator consensus se-
quence, 5'-PyPyCAPyPyPyPyPy-3' [39]. The Ymut2 site,
which is the most important site for controlling basal ex-
pression, overlaps a potential initiator site fitting the
consensus (5' CTT CCC TTT TCC 3') for the ribosomal
protein Inr family with only one mismatched base [40].
Interestingly, both Ymut1 and Ymut2 are positioned near
the most upstream transcriptional start site [25].
The initiator (Inr) element has been shown to be critical
in positioning RNA polymerase II complex for transcrip-
tion initiation in TATA-less promoters [39]. Since the
CD5 promoter does not contain a TATA box, these initi-
ator binding sites may play a more important role in es-
tablishing transcription initiation.
Several Inr binding protein have been identified: TFII-I
[41], YY1 [42, 43], and a 150 kDa TATA binding protein
(TBP) associated factor (TAFII150) [44]. Recognition of
the Inr element by these Inr binding proteins (ITF) pro-
vides a way for formation of transcription competent
complex via their interaction with TBP or with other sub-
units of RNA polymerase II. Thus we suggest that CD5Y
region interacts with these ITFs to regulate transcrip-
tion.
Like CD5Y, CD5X region does not contain any consensus
transcription factor binding sites. This region is not nec-
essary for basal CD5 transcription but it affects the over-
all level of CD5 transcription obtained with the full
length 3 Kb promoter. At least three specific pro-
tein:DNA complexes are formed in EMSA using the
CD5X oligonucleotides. We speculate that proteins bind-
ing to the CD5X region may interact with other upstream
transcription factors, e.g., Ets-1, rather than with pro-
teins binding to the CD5Y region. This interaction, we
suggest, acts to stabilize a transcriptional competent
complex and thereby to increase the CD5 expression to
normal levels.
This suggestion underlies the model proposed in figure 6
for regulating CD5 expression in T cells. In this model,
the CD5Y region sets up the basal transcription machin-
ery by interacting with components in the RNA polymer-
ase II transcription complex and/or with transcription
initiators, since CD5 lacks a TATA box for establishing a
typical RNA polymerase II trancription initiation com-
plex. The CD5X region recruits transcription factors to
the upstream 43 bp region identified as necessary for
overall CD5 expression.
The proteins binding to the CD5X region in this model
recruit Ets-1 protein (and perhaps other Ets family mem-
bers) to the Ets binding site. Alternatively, these proteins
help to alleviate the internal Ets-1 inhibition domains
and stabilize the binding of Ets-1 to its cognitive site [33,
34, 45]. In any event, they facilitate the interaction of
Ets-1 with other factors to form activate transcription
and increase it from the basal to the overall level.
Our studies here focus on characterizing the promoter el-
ements responsible for regulating the constitutive CD5
expression in unstimulated T cells. These elements, we
have shown, exist in a region proximal to the translation
start and quite distant from an enhancer element shown
in other studies [46,47,48] to regulate the activation of
CD5 expression in BCR-stimulated LPS-induced B cell
blasts. This enhancer element, located at approximatelyBMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
2 kb upstream of the translation start on the CD5 pro-
moter, is dependent on NF-AT activation to induce CD5
expression in anti-IgM stimulated primary splenic cells
cultured with LPS for 3 days [48]. It is reported to inter-
act with proteins in the proximal region of the CD5 pro-
moter, which contains the all three regions characterized
here.
An Ets binding site also has been implicated in the activ-
ity of the enhancer discussed above. In addition, this
CD5 response to BCR stimulation has been shown to be
mediated in part by vav-2, which activates of NF-AT
[49]. Our studies with constitutive expression of CD5 on
B cells are still in progress. However, preliminary evi-
dence suggests that unlike the stimulated CD5 expres-
sion in these other studies, the low-level constitutive
expression of CD5 on the M12 B cell line is enabled by the
same 43 bp regulatory region that we have shown here is
sufficient to induce full constitutive CD5 expression on T
cells.
Figure 6
EMSA analysis with oligonucleotides corresponding to the CD5X region. The 32P-labeled CD5X oligonucleotide (5'
AGG CCT AAG TTG ACA GTT CAA CTT CAA ACA CTC GAG 3') was incubated with EL4 nuclear extract (lane 2-6).
Competitive EMSA was performed with 100-fold excess specific oligonucleotide, X oligos (lane 3), or irrelevant oligos: Y oligos
(lane 4); CK oligos (lane 5); and KE (lane 6). The protein:DNA complexes specific to the CD5X oligonucleotides are indicated
with arrows. F indicates the migration of the free probe.
EMSA analysis with oligonucleotides corresponding to the CD5Y region. The 32P-labeled CD5Y oligonucleotide (5'
AGG CCT CAC AGG CCC ACA CTG CCT GCT TCC CTG GAG 3') was incubated with EL4 nuclear extract and subse-
quently resolved in EMSA. The protein:DNA complexes specific to the CD5Y oligonucleotides were indicated with arrows. In
lane 1 is 32P-labeled CD5Y oligos alone; lanes 2-6, 32P labeled CD5Y oligos plus EL4 nuclear extract. Competitive EMSA are
shown on lanes 3-6 with addition of 100-fold molar excess oligonucleotides for competition: CD5Y (lane 3), CD5X (lane 4),
CK (lane 5), and KE (lane 6). The protein:DNA complex specific to the CD5Y oligonucleotides are indicated with arrows. F
indicates the migration of the free probe.BMC Molecular Biology (2001) 2:5 http://www.biomedcentral.com/1471-2199/2/5
Materials and Methods
Plasmids
The reporter constructs were created as follows: The 3 kb
genomic fragment upstream of the CD5 translation start
was excised by restriction digest with HindIII and NcoI
from p12-1 [32], a genomic DNA plasmid containing the
first two CD5 exons and the 3 kb upstream region. Vari-
ous deletion constructs were created by first digesting
the 3 kb genomic fragment (HindIII-NcoI) with various
restriction enzymes, blunted with Klenow DNA polymer-
ase, and then cloned into pGL2Basic luciferase reporter
plasmid. The resulting deletion reporter plasmids were
further modified by mutating the blunted Nco I sites to
Bgl II sites. The structure of all reporter constructs were
confirmed by DNA sequencing (Amplitaq sequencing kit,
Perkin-Elmer).
The Ets-1 expression plasmid, pEVRF-ets-1, contains the
parental expression plasmid pEVRF0 and the insertion
of the Ets-1 cDNA. The control expression plasmid,
pEVRF0, contains the human CMV enhancer/promoter,
the translation initiation from HSV thymidine kinase,
splicing and polyadenylation signals from the rabbit β -
globin gene, and the SV40 origin of replication in the
pSP65 bacterial plasmid.
For internal control in transient transfections, we used
PON405, which contains LacZ under the transcriptional
control of human CMV promoter. The resulting β -galac-
tosidase activity was used to normalize transient trans-
fection results. Mutagenized constructs based on StuI B
or HincII plasmid are described in the site-directed mu-
tagenesis section.
Cell culture
Murine thymoma EL4 cells and murine CD5+ B cells,
M12, were maintained in RPMI 1640 medium supple-
mented with 10% (v/v) 1:1 fetal calf serum and horse se-
rum, 2 mM glutamine, 100 U/ml penicillin, 0.05 mM
streptomycin, and 50 nM 2-mercaptoethanol. All cell
cultures were maintained at 37° C with 7% CO2.
Transient transfections
EL4 or M12 cells were grown to 1 - 2 ×  106 cells per ml,
centrifuged and resuspended at a concentration of 107
cells/300 µ l in complete RPMI medium. Each aliquot
(300 µ l) of the cells was electroporated along with 15 µ g
of reporter constructs and 5 µ g of PON405, in a Bio-Rad
gene pulser at 250 volts with 960 µ D capacitance. The
electroporated cells were diluted in 3 ml of complete
RPMI 1640 medium and maintained at 37° C for 36-48
hours. At the time of analysis, 1.5 ml of the transfected
cells were transferred to eppendorf tubes, centrifuged
and lysed in 320 µ l of lysis buffer (60 mM Na2HPO4, 40
mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, and 0.1% Tri-
ton X-100 at pH7).
Luciferase activity was measured using a luminometer
(Analytical Luminescence Laboratory). The β -galactosi-
dase activity in each cell lysate was measured in the 4-
Methylumbelliferyl-β -D-Galactoside (MUG) assay and
was used to normalize the luciferase activity analyzed in
each cell lysate. The reported values represent the aver-
Figure 7
Proposed model for CD5 transcription. Proposed model depicting the potential interaction between Ets-1 and proteins
binding to the CD5X and CD5Y regions in forming a transcriptional competent complex.
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age of three independent transfections, with standard
deviation as error bars. Each experiment was repeated at
least twice.
Nuclear extract isolation
Nuclear extracts were isolated from EL4 and M12 as fol-
lows. The cultured cells were grown to 1-2 ×  106 cells/ ml,
then collected and hypotonically swollen in buffer A (10
mM Hepes pH7.9, 10 mM KCl, 2 mM MgCl2, 0.1 mM ED-
TA, 1 mM DTT, and 1 mM PMSF) before lysis with NP40.
The nuclear proteins were extracted by resuspending the
nuclear pellet with buffer C (50 mM Hepes pH7.9, 300
mM NaCl, 50 mM KCl, 0.1 mM EDTA, 10% glycerol, 1
mM DTT, and 1 mM PMSF). Nuclear extracts were quan-
titated using Bio-Rad protein assay (Bio-Rad Laborato-
ries, CA).
Sequence analysis and site-directed mutagenesis
The consensus transcription factor binding sites were
identified by comparing the CD5 promoter sequences
against Transcription Factor Database using Quest pro-
gram (Intelligenetics Corporation). The mutagenesis
primers corresponding to each of the five regions, Ets
(mutE), κ E2 (mutK), CCAAT (mutC), CD5X (Xmut1, 2,
and 3), and CD5Y (Ymut1 and 2) were synthesized at the
Protein and Nucleic Acid Facility, Stanford University.
The mutC, mutK, mutE, Xmut, and Ymut mutagenesis
primers were first PCR amplified with GL2 primer (5'
CTT TAT GTT TTT GGC GTC TTC CA 3') using StuI B
plasmid as template to generate megaprimers. For the
HincII B plasmid, Xmut and Ymut mutagenesis primers
were used in conjunction with GL2 for PCR amplifica-
tion.
The mutagensis primers were as follows: for mutC, 5'
GCTCGACCT CCA TTC TAA TGT GGG CAG GTG GTT
TCA CAG 3'; mutK, 5' CCA TTC TAA TTG GGG CTT TTT
GTT TCA CAG GGA GGA AGT 3'; mutE, 5' TTT CAC AGG
GAC CTT GTT GAC AGT TCA ACT TCA AAC 3'; Xmut1,
5' CAC AGG GAG GAA GTT CTG TCA TCA ACT TCA
AAC AGG 3'; Xmut2, 5' GAG GAA GTT GAC AGT CTA
AGA CTA AAC AGG GTT GGC AGT 3'; Xmut3, 5' TGA
CAG TTC AAC TTC GTT AGT GGT TGG CAG TGA CAC
3'; Ymut1, 5' TGG CAG TGA CAC AGG TGT ACT CTG
CCT GCT TCC CCT 3'; and Ymut2, 5' ACA CAG GCC CAC
ACT GAT GCG TTC CCC TTT CCA CCC CTG 3'. The un-
derlined sequences denote the consensus transcription
factor binding site. Boldfaced sequences indicate the mu-
tated base pairs.
Each of the megaprimers was purified and subsequently
amplified with GL1 primer (5' TGT ATC TTA TGG TAC
TGT AAC TG 3'), using StuI B or HincII B plasmid as a
template. The resulting PCR products were gel isolated,
digested with BglII and MluI, and cloned into the pGL-
Basic luciferase reporter construct. E. coli clones carry-
ing the mutagenized plasmids were identified by colony
lifts and each mutagenized plasmid was sequenced to
confirm the mutations.
EMSA
The double stranded oligonucleotide probes were end-
filled with Klenow DNA polymerase and α -32P-dGTP.
The double stranded oligos used were as follows: for the
Ets binding site on the CD5 promoter, 5' CGC GTA CAG
GGA GGA AGT TGA CCT CGA 3'; for the oligonucle-
otides containing the CD5X region, 5' AGG CCT AAG
TTG ACA GTT CAA CTT CAA ACA CTC GAG 3'; and for
the CD5Y oligo, 5' AGG CCT CAC AGG CCC ACA CTG
CCT GCT TCC CTG GAG 3'. The probes were purified us-
ing the Qiaquick nucleotide removal kit (Qiagen, Germa-
ny), and 5 ×  105 cpm of the probe were incubated with
nuclear extracts at room temperature for 30 minutes.
Competitor oligonucleotides or inhibition antibodies
were added 20 minutes before the addition of the radi-
olabeled probe DNA.
The competitor oligos are as follows: CD5 κ E2, 5' GTA
CCT AGG GGC AGG TGG TTT CAC GCG 3'; CD5 CK, 5'
CCT CCA TTC TAA TTG GGG CAG GTG GTT TCA CAG
G 3'; and CD5 KE, 5' AGG CCT GGG GCA GGT GGT TTC
ACA GGG AGG AAG TTC TCG AG 3'. The CK oligo con-
tains CD5 κ E2 and CCAAT sites. The KE oligo contains
κ E2 and Ets sites. The binding reaction consisted of 10
mM Hepes pH7.9, 10 mM Tris-HCl pH 7.5, 100 mM Na-
Cl, 15 mM KCl, 0.5 mM EDTA, 1 mM dithiothreitol, 10%
glycerol, and 2 µ g dIdC.
The protein:DNA complexes were resolved by electro-
phoresis through 5% nondenaturing polyacrylamide gels
in 0.25 X TBE buffer. Electrophoresis was conducted for
2 1/2 hours at 150 V. The gels were then vacuum dried
and exposed to X-ray film overnight with an intensifying
screen screen at -80° C.
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